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Lepra reactions are the immune reactions of leprosy. They can be
divided into type 1, type 2 [erythema nodosum leprosy (ENL)], and
type 3 reactions (Lucio phenomenon). The typical clinical charac-
teristics of ENL are crops of tender and erythematous papulopla-
ques accompanied by constitutional symptoms. Here, we
reported a case of ENL with generalized eruptions studded with
pustules that was misdiagnosed as antiphospholipid syndrome
(APS) due to the presence of immunoglobulin (Ig)M isotypes of
antiphospholipid (aPl) antibodies.
A 24-year-old Indonesian woman presented with painful erup-
tions on the trunk and limbs for 5months. Four years ago, she expe-
rienced her ﬁrst spontaneous abortion. Six months later, when she
was pregnant again, asymptomatic erythematous papuloplaques
developed on her calves, which subsided partially after delivery.
APS was suspected after her second spontaneous abortion,
following the detection of IgM isotypes for both anti-cardiolipin
(aCL antibody; 13 U/mL) and anti-beta-2 glycoprotein antibodies
(anti-b2GP1 antibody; 338 U/mL). Prednisolone (10 mg daily),
aspirin (100 mg daily), and hydroxychloroquine (100 mg twice a
day) were prescribed. She had no pregnancy morbidity, but experi-
enced a gradual onset of numerous tender erythematous papulo-
plaques and nodules with pustules on her trunk and four limbs
(Figure 1AeC), accompanied by fever, chills, and malaise 6 months
after the regular treatments for suspicious APS. Therefore, the treat-
ments were discontinued. Laboratory evaluation revealed leukocy-
tosis (13,600/uL) with prominent neutrophilia (78.4%) and high CRP
(184.3 mg/dL). The rapid plasma regain was negative, and histopa-
thology of the pustular lesion showed granulomatous inﬂamma-
tions with massive intra-epidermal and intradermal neutrophil
inﬁltrates with foamy macrophages containing globi (Figures 2A
and 2B). Intradermal nerve bundles were also involved
(Figure 2C), and numerous bacilli were found by Fite staining, but
not by ordinary acid-fast staining (Figure 2D). Lepromatous leprosy
was diagnosed. One month after the initiation of multidrug therapy
(MDT) with thalidomide, prednisolone, dapsone, clofazimine, and
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mation hyperpigmentation at the end of MDT for 1 year.
ENL is an inﬂammatory condition of leprosy that most
commonly occurs in patients with a high bacterial index or after
starting MDT and other highly bactericidal drugs, including oﬂoxa-
cin.1 None of the drugs used by the presenting case for the suspi-
cious aPL syndrome had been reported to induce ENL. In fact,
steroids were one of the elements included in ENL treatments.2
Constitutional symptoms, including fever and malaise, are com-
mon. Neutrophils are the signature cells, with clinical presentation
potentially resembling erythema nodosum, showing crops of pain-
ful papulonodules. However, pustular lesions have rarely been re-
ported. Dave et al1 ﬁrst reported one case of ENL with multiple
pustules after switching from World Health Organization (WHO)-Figure 1 Numerous erythematous papules, plaques, and nodules, with pustules scat-
tered on the (A) trunk and (B, C) limbs.
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Figure 2 Histopathology is consistent with lepromatous leprosy. (A) Parakeratosis
with neutrophilic inﬁltrates (hematoxylin and eosin stain; original magniﬁcation:
40). (B) Massive inﬁltrate of neutrophils and presence of foamy macrophage with
globi (hematoxylin and eosin stain; original magniﬁcation: 400). (C) Neutrophils,
lymphocytes, foamy macrophages, and globi aggregate around a nerve bundle (hema-
toxylin and eosin stain; original magniﬁcation: 400). (D) Fite staining reveals the
presence of numerous acid-fast bacilli in macrophages (Fite staining; original magniﬁ-
cation: 400).
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granulomata with a prominent neutrophilic inﬁltrate, which
encroached into the epidermis to form an abscess. Nine years later,
Adhe et al3 analyzed the clinical and histopathologic presentation
of 64 leprosy cases, reporting that three of 42 patients with type
2 reactions presented clinically with pustules and lesions showing
intra-epidermal neutrophils pathologically. The authors concluded
that the dense collection of neutrophils in the epidermis and
dermis was probably responsible for the clinical pustules in ENL le-
sions.3 In 2014, Ghorpade2 reported another case of ENL with
generalized pustules after treatment with WHO multibacillary-
MDT for 3 months. Histology of a biopsy from one pustular lesion
showed a prominent inﬂammatory inﬁltrate with numerous neu-
trophils and foamy cells in the dermis. Furthermore, the neutro-
philic inﬁltrate extended into the perforated epidermis to form
subcorneal pustules. It was suspected that inﬂammatory insult
may cause the release of cytokines, damaging the basement mem-
brane and dermal collagen, and thereby inducing perforating chan-
nels.2 Pustular ENL is a rare manifestation that is possibly triggered
by initiation of therapy, pregnancy, or parturition to induce the for-
mation of immune complexes that release cytokines to damage
normal dermal structures with the inﬂux of neutrophils.
This case was suspected to have APS based on the presence of
the IgM isotype of the b2GP1 antibody and the aCL antibody,
although she did not meet the revised Sapporo classiﬁcation
criteria for APS due to inadequate clinical evidence of thrombosis.
aPl antibodies were reportedly associated with leprosy. Sene
et al4 reported that the mean prevalence of aCL and anti-b2GP1antibodies in lepromatous or borderline leprosy was ~43% and
~45%, respectively. Ribeiro et al5 compared the frequency of anti-
phospholipid antibodies according to isotype distribution in
healthy controls, leprosy patients, and a group of primary APS pa-
tients. Increased levels of aPL antibodies were observed in leprosy
patients and the APS group. In contrast to APS, the predominant
isotype in leprosy was IgM rather than IgG. One study reported
77 of 158 leprosy patients with positive aPL, with 31 of themmain-
taining high titers of IgM aPL antibodies 5 years later.6 However,
two studies had failed to show the clinical or statistical evidence
correlating the presence of aPL antibodies in leprosy to any throm-
botic event.4,6 Whether the aPL antibodies in leprosy increase the
risk of thrombosis needs further clariﬁcation. Therefore, the bene-
ﬁts of anticoagulants or antithrombotic agents were unclear.
Leu247Val and Trp316Ser single-nucleotide polymorphisms were
suspected to represent genetic risk factors for anti-b2GP1 antibody
production in multibacillary leprosy patients.7 Baeza et al8 discov-
ered a positive correlation between anti-mycolic- non-bilayer ar-
rangements and aCL antibodies in leprosy patients, suggesting
that antibodies to non-bilayer lipid arrangements may represent
the pathogenic mechanism in lepromatous leprosy.
In conclusion, the presence of aPl antibodies in leprosy, espe-
cially the IgM isotype, is not only a coincidence, but also represent
a genetic predisposition and pathogenic process. Clinicians should
bear in mind the possibility of pustular-eruption development in
patients with ENL, and leprosy should be included in differential
diagnosis in the presence of IgM isotype-aPl antibodies.
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